FLI1 and neoplasm: This interaction has now been shown to alter tumor growth in Ewing’s Sarcoma patients, where the EWS-FLI1, an oncogenic fusion protein that drives tumor growth in 90% of patients, is constrained by a loss of ETV6 (201).